COMPOSITION:
Each 2ml ampoule contains: Pancuronium Bromide BP 4mg.

PHARMACOLOGY:
Pancron (Pancuronium Bromide) is a non-depolarizing neuromuscular blocking agent.
It is a member of bis-quaternary ammonium steroids.
Pancron, in extensive pharmacological and clinical studies has shown to be five times as potent as tubocuraine with minimal cardiovascular has histamine releasing action.
Pancron does not cause muscle fasciculations.
All neuromuscular blocking agents are administered parenterally, mostly intravenously.
After I.V. administration pharmacological effects are achieved within 5 minutes and start to wear off in about 20 minutes. The brief duration of paralysis following the initial dose in due to redistribution of the drug. Elimination half-life (plasma) is 1 to 2 hours. Excretion is primarily renal and small quantities appear in bile.

INDICATION:
Main clinical use of Pancron (Pancuronium Bromide) is as an adjuvant in surgical anaesthesia to obtain relaxation of skeletal muscles, particularly of the abdominal wall. Muscle relaxation is also of value in various orthopaedic procedures (reduction of dislocated joints and fractures).
Pancron is also used to facilitate intubation with an endotracheal tube.
Pancron is also indicated in other surgical procedures of short durations like laryngoscopy, bronchoscopy, and endoscopy.

DOSAGE AND ADMINISTRATION:
The following doses may serve as general guidelines for initial and maintenance dose requirements of Pancron to assure appropriate muscle relaxation throughout medium and long duration surgical procedures.

FOR INTUBATION AND SUBSEQUENT SURGERY:
0.08 to 0.1 mg / kg body weight I.V.

FOR SURGICAL PROCEDURES AFTER
INTUBATION WITH SUCCINYL-CHOLINE:
0.04 to 0.06 mg / kg body weight I.V.

FOR MAINTENANCE OF MUSCLE RELAXATION:
0.01 to 0.02 mg / kg body weight I.V.

Pancron is administered intravenously only, preferably as a bolus injection into the line of a running infusion. Pancron should only be used with following infusion fluids:
0.9% sodium chloride solution.
5% dextrose solution.
Ringer's lactate solution.

CONTRA-INDICATION:
Pancron must not be administered to individuals with known sensitivity to Pancuronium Bromide.

USE DURING PREGNANCY AND LACTATION:
Like other medicines Pancron should not be used during pregnancy and lactation.

CAESAREAN SECTION:
Studies with Pancron have shown its safety for use in caesarean section.

INTERACTION WITH OTHER MEDICAMENTS:
The following drugs potentiate the action of Pancron:
Halothane, thiopentone, succinyl-choline, diuretics, ß-adrenergic blockers, metronidazole and magnesium salt.
The following medicines decrease the effects of Pancron:
Neostigmine, nor-adrenaline and theophylline.

SIDE-EFFECT:
Pancron is generally very well tolerated. Few side-effects are as follows:

CARDIOVASCULAR:
Minor cardiovascular effects (moderate rise in heart rate).
OPHTHALMIC:
Pancron has been reported to produce significant (20%) fall in normal and elevated intraocular pressure.
ANAPHYLACTIC REACTIONS:
These reactions are rarely seen with Pancron.

OVER DOSAGE:
In the event of over dosage cholinesterase inhibitor e.g. Neostigmine (Neo-Choline) should be administered.

STORAGE:
Pancron must be stored in the refrigerator at 2-8° C.

PRESENTATION:
Pack of 10x2ml ampoules.